Neuromuscular Disease News

LAS VEGAS — Clinicians should make specific product recommendations to patients for over-the-counter topical pain medications to help prevent confusion among hundreds of analgesic choices at the pharmacy.

LAS VEGAS — Recognition of the fear avoidance model, which is how one develops chronic pain through avoidant behavior, can help clinicians treat pain in patients, according to a presenter at PAINWeek 2022.

Following a hybrid conference last year, PAINWeek 2022 will be back in full swing, as this year’s meeting will be fully in-person.

The American Society of Interventional Pain Physicians and the Interventional Pain Management Tracks will return to the PAINWeek National Conference, taking place Sept. 6-9 in Las Vegas.

Vamorolone demonstrated efficacy and safety in the treatment of boys with Duchenne muscular dystrophy over a 24-week treatment period and may be safer than prednisone, according to a study published in JAMA Neurology.

The Parkinson’s Foundation has announced $1.1 million in funding for the Institutional Movement Disorder Fellowship Program and the Nurse Practitioner Fellowship in Movement Disorders.

Biogen Inc. announced that the FDA has accepted a new drug application for tofersen, an investigational drug to treat superoxide dismutase 1 ALS.

The Kessler Foundation received multiple grants from the New Jersey Health Foundation for research projects that aim to improve cognition and mobility in patients with neurological disabilities, the foundation announced in a press release.

Gene therapy company uniQure has announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing phase 1/2 clinical trial of AMT-130 for treatment of Huntington’s disease.

Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022.